MarketCap
Facebook
X
TelegramGeschäftsbericht 2023
hinzugefügt 15.03.2024
Brickell Biotech Operativer Cashflow 2011-2026 | BBI
Operativer Cashflow Jährlich Brickell Biotech
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.34 M | -19.3 M | -36.1 M | -20 M | -36 M | 3.97 M | -8.6 M | -8.39 M | - | - | -29.8 M | -17.2 M | -3.64 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 3.97 M | -36.1 M | -16.3 M |
Operativer Cashflow Vierteljährlich Brickell Biotech
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -4.48 M | - | - | -12.5 M | -9.54 M | - | - | -20.2 M | -5.89 M | - | -15.3 M | -11.3 M | -6.61 M | - | -21.9 M | -9.5 M | -5.32 M | - | 7.62 M | -8.63 M | -4.57 M | - | -6.9 M | -3.97 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -8.38 M | - | -11.5 M | -6.97 M | -8.01 M | - | 976 K | -15 M | -8.71 M |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 7.62 M | -21.9 M | -8.55 M |
Operativer Cashflow anderer Aktien in der Pharmaeinzelhändler
| Name | Operativer Cashflow | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
Cerus Corporation
CERS
|
4.84 M | $ 2.68 | -1.65 % | $ 511 M |  USA |
 |
AgeX Therapeutics
AGE
|
-18 M | - | -10.17 % | $ 12.2 K | USA |
 |
BioNTech SE
BNTX
|
890 M | $ 96.56 | -2.81 % | $ 27.2 B | Germany |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M |  China |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
AlloVir
ALVR
|
-38.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B | France |
 |
Edesa Biotech
EDSA
|
-4.89 M | $ 15.71 | -2.48 % | $ 50.2 M | USA |
 |
Evogene Ltd.
EVGN
|
-24.7 M | $ 0.78 | 4.15 % | $ 27.9 M |  Israel |
 |
Athira Pharma
ATHA
|
-45.7 M | - | - | $ 269 M | USA |
 |
Applied Molecular Transport
AMTI
|
-93.9 M | - | - | $ 10.1 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M | Israel |
 |
AstraZeneca PLC
AZN
|
5.96 B | - | - | $ 96.9 B | Britain |
 |
Atreca
BCEL
|
-80.7 M | - | -11.76 % | $ 5.79 M | USA |
 |
Berkeley Lights
BLI
|
-47.5 M | - | -7.31 % | $ 87 M | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
-6.32 M | - | - | $ 2.46 M | Israel |
 |
Calithera Biosciences
CALA
|
-66.3 M | - | -10.95 % | $ 876 K | USA |
 |
Genmab A/S
GMAB
|
1.33 B | - | - | $ 16.9 B |  Danmark |
 |
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | USA |
 |
CymaBay Therapeutics
CBAY
|
-72.5 M | - | - | $ 3.45 B | USA |
 |
ChemoCentryx
CCXI
|
-75.6 M | - | - | $ 3.74 B | USA |
 |
Harmony Biosciences Holdings
HRMY
|
348 M | - | - | $ 1.87 B | USA |
 |
ImmuCell Corporation
ICCC
|
2.48 M | $ 8.78 | 0.71 % | $ 79.2 M | USA |
 |
Caladrius Biosciences
CLBS
|
-19.4 M | - | -16.75 % | $ 25.8 M | USA |
 |
Innoviva
INVA
|
197 M | $ 22.78 | -0.91 % | $ 1.54 B | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-53.7 M | - | - | $ 231 M | USA |
 |
Innate Pharma S.A.
IPHA
|
-58.5 M | - | - | $ 235 M | France |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M |  Canada |
 |
ACADIA Pharmaceuticals
ACAD
|
158 M | $ 22.3 | 0.5 % | $ 3.7 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-6.98 M | - | -2.5 % | $ 5.88 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
Jaguar Health
JAGX
|
-23.7 M | $ 2.83 | -13.08 % | $ 6.6 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-147 M | - | - | $ 2.18 B | USA |
 |
AIkido Pharma
AIKI
|
22.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Cardiff Oncology
CRDF
|
-37.9 M | - | - | $ 109 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
66.5 M | - | - | $ 2.02 B | USA |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
-116 M | - | - | $ 28.6 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
-81.6 M | $ 26.7 | 0.15 % | $ 1.44 B | Britain |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.95 M | - | - | $ 5.75 M | Israel |
 |
Eiger BioPharmaceuticals
EIGR
|
-74.5 M | - | -9.21 % | $ 2.55 M | USA |
 |
Kamada Ltd.
KMDA
|
-8.82 M | $ 8.24 | -0.62 % | $ 260 M | Israel |
 |
Eloxx Pharmaceuticals
ELOX
|
-31.8 M | - | -5.68 % | $ 8.28 M | USA |